Trial · NCT01677507
Glaucoma Biomarkers
NCT01677507, Phase 4, Completed, University of Michigan; results first posted 2017-09-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Glaucoma Biomarkers. Trials, record NCT01677507. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01677507
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glaucoma Biomarkers
- NCT number
- NCT01677507
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 135 participants, actual
- Lead sponsor
- University of Michigan
- Conditions
- Glaucoma, Healthy
- Interventions
- Variation in eye pressure response to timolol and latanoprost treatment
- First posted
- 2012-09-03
- Last updated
- 2017-09-13
- Results first posted
- 2017-09-13
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Variation in Eye Pressure Between Individuals. | Measurement after 1 week of drug treatment | Eye pressure is a steady state quantitative trait that is measured in mm Hg. Eye pressure is determined by the following physiological factors (units of measure): eye fluid or aqueous humor production (microliters/minute), aqueous humor outflow (microliters/minute), outflow resistance (microliters/minute/mm Hg) and venous pressure (mm Hg) of the eye. All of these physiological factors will be determined under baseline condition and under glaucoma drug treatment. |
| Secondary | Variation in Aqueous Flow Between Individuals. | 1 week after treatment | Aqueous flow production (microliters/minute) will be determined under baseline condition and under glaucoma drug treatment. |
| Secondary | Variation in Episcleral Venous Pressure. | 1 week treatment | Episcleral venous pressure (mm Hg) of the eye will be determined under baseline condition and under glaucoma drug treatment. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Variation in Eye Pressure Between Individuals. | Measurement after 1 week of drug treatment | mmHg | MEAN | |
| SECONDARY | Variation in Aqueous Flow Between Individuals. | 1 week after treatment | These measurements can be difficult for participants to tolerate, so sometimes values are missing. | microliters/min | MEAN |
| SECONDARY | Variation in Episcleral Venous Pressure. | 1 week treatment | These measures can be difficult to obtain, so sometimes participants do not tolerate it and some values are missing. | mmHg | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Variation in Eye Pressure Between Individuals. | Timolol | RIght Eyes | 11.5 | Standard Deviation 3.2 | mmHg |
| Variation in Eye Pressure Between Individuals. | Latanoprost | RIght Eyes | 11.3 | Standard Deviation 3.2 | mmHg |
| Variation in Eye Pressure Between Individuals. | Timolol | Left Eyes | 11.0 | Standard Deviation 3.0 | mmHg |
| Variation in Eye Pressure Between Individuals. | Latanoprost | Left Eyes | 11.0 | Standard Deviation 2.9 | mmHg |
| Variation in Aqueous Flow Between Individuals. | Timolol | Right eye | 1.9 | Standard Deviation 0.6 | microliters/min |
| Variation in Aqueous Flow Between Individuals. | Latanoprost | Right eye | 2.8 | Standard Deviation 0.9 | microliters/min |
| Variation in Aqueous Flow Between Individuals. | Timolol | Left eye | 2.0 | Standard Deviation 0.6 | microliters/min |
| Variation in Aqueous Flow Between Individuals. | Latanoprost | Left eye | 3.0 | Standard Deviation 1.0 | microliters/min |
| Variation in Episcleral Venous Pressure. | Timolol | Right eye | 7.6 | Standard Deviation 1.5 | mmHg |
| Variation in Episcleral Venous Pressure. | Latanoprost | Right eye | 7.7 | Standard Deviation 1.9 | mmHg |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Initial Assignment | STARTED | Timolol Followed by Latanoprost | 63 | |
| Initial Assignment | STARTED | Latanoprost Followed by Timolol | 58 | |
| Initial Assignment | COMPLETED | Timolol Followed by Latanoprost | 63 | |
| Initial Assignment | COMPLETED | Latanoprost Followed by Timolol | 56 | |
| Initial Assignment | NOT COMPLETED | Timolol Followed by Latanoprost | 0 | |
| Initial Assignment | NOT COMPLETED | Latanoprost Followed by Timolol | 2 | |
| Second Assigment | STARTED | Timolol Followed by Latanoprost | 63 | |
| Second Assigment | STARTED | Latanoprost Followed by Timolol | 56 | |
| Second Assigment | COMPLETED | Timolol Followed by Latanoprost | 60 | |
| Second Assigment | COMPLETED | Latanoprost Followed by Timolol | 51 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Timolol | 0 | 119 |
| Total, all-cause mortality | Latanoprost | 0 | 121 |
| Total, other adverse events | Timolol | 0 | 119 |
| Total, other adverse events | Latanoprost | 0 | 121 |
| Total, serious adverse events | Timolol | 0 | 119 |
| Total, serious adverse events | Latanoprost | 0 | 121 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01EY022124 | Aqueous Humor Dynamic Components that Determine Intraocular Pressure Variance | MOROI, SAYOKO E | OHIO STATE UNIVERSITY | NATIONAL EYE INSTITUTE | 2012 to 2022 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Timolol vs Latanoprost: deaths from any cause | Trial comparisons |
| Timolol vs Latanoprost: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01677507
GET https://conductscience.org/api/trials/v1/NCT01677507/registered